We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

120 hedge funds and large institutions have $2.42B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2014 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 43 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 18

4% more funds holding

Funds holding: 115 → 120 (+5)

12% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 43

30% less call options, than puts

Call options by funds: $8.81M | Put options by funds: $12.6M

31% less capital invested

Capital invested by funds: $3.53B → $2.42B (-$1.11B)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
120
Holders Change
+5
Holders Change %
+4.35%
% of All Funds
3.48%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
23
Increased
38
Reduced
43
Closed
18
Calls
$8.81M
Puts
$12.6M
Net Calls
-$3.75M
Net Calls Change
+$28.8M

Top Buyers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
+$40.5M
2
CWAM
Columbia Wanger Asset Management
Illinois
+$29.1M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$19.5M
4
TCM
Tekla Capital Management
Massachusetts
+$16M
5
BB
BB Biotech
Switzerland
+$14M

Top Sellers

Rank Fund Capital Flow
1
CCI
Columbus Circle Investors
-$27.4M
2
Norges Bank
Norges Bank
Norway
-$18.9M
3
PCM
Palisade Capital Management
New Jersey
-$12.7M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$11.9M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
-$5.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$8.47M -$70.3K -982 -0.8%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$8.44M -$1.22K -17 -0%
JP Morgan Chase
28
JP Morgan Chase
New York
$8.01M -$129K -1,800 -2%
O
29
OrbiMed
New York
$7.64M – – –
Bank of New York Mellon
30
Bank of New York Mellon
New York
$7.57M +$466K +6,506 +6%
Wellington Management Group
31
Wellington Management Group
Massachusetts
$7.25M -$113K -1,582 -1%
CAM
32
Cormorant Asset Management
Massachusetts
$6.88M +$7.16M +100,000 New
AC
33
Ascend Capital
California
$5.85M +$6.09M +85,000 New
TCIM
34
TIAA CREF Investment Management
New York
$5.71M -$341K -4,762 -5%
Millennium Management
35
Millennium Management
New York
$4.84M +$5.04M +70,423 New
California Public Employees Retirement System
36
California Public Employees Retirement System
California
$4.61M – – –
GC
37
Guggenheim Capital
Illinois
$4.51M +$874K +12,206 +23%
BIM
38
BlackRock Investment Management
Delaware
$4.01M -$6.16K -86 -0.1%
Charles Schwab
39
Charles Schwab
California
$3.97M +$200K +2,796 +5%
Macquarie Group
40
Macquarie Group
Australia
$3.51M +$958K +13,376 +36%
UBS AM
41
UBS AM
Illinois
$3.28M -$158K -2,200 -4%
Asset Management One
42
Asset Management One
Japan
$2.86M +$2.95M +41,258 New
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$2.82M +$139K +1,940 +5%
PAMU
44
Pictet Asset Management (UK)
United Kingdom
$2.78M -$5.64M -78,800 -66%
PC
45
Pier Capital
Connecticut
$2.73M -$3.14M -43,847 -53%
PAM
46
Paradigm Asset Management
New York
$2.28M +$2.38M +33,200 New
Deutsche Bank
47
Deutsche Bank
Germany
$2.16M +$1.57M +21,947 +231%
TA
48
Teachers Advisors
New York
$2.07M – – –
Renaissance Technologies
49
Renaissance Technologies
New York
$1.8M +$1.88M +26,200 New
ProShare Advisors
50
ProShare Advisors
Maryland
$1.76M -$350K -4,884 -16%
1
2
3 4 5

GEVA Hedge Fund Activity: Q3 2014 in Review

120 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q3 2014, worth a combined $2.42B — down 31% from $3.53B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new GEVA positions and 18 closed out — a net gain of 5 holders — while 38 added to existing stakes and 43 trimmed.

The largest buyer was Wells Fargo, adding an estimated $40.5M. The largest seller was Columbus Circle Investors, exiting entirely with an estimated $27.4M sold.

  • 120 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q3 2014, up from 115 in Q2 2014.
  • Funds reported $2.42B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q3 2014, down 31% quarter-over-quarter.
  • 23 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q3 2014 and 18 closed out, a net change of +5 holders.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q3 2014 was Wells Fargo, an estimated $40.5M added.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q3 2014 was Columbus Circle Investors, an estimated $27.4M sold.

Based on aggregated 13F filings for Q3 2014.